Qiming Venture Partners Weekly | Portfolio Company Updates Vol. 31, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Editor's Note: The "Qiming Weekly" column is published regularly every week, rounding up funding news and development updates from Qiming Venture Partners' portfolio companies.
In the wave of technology and innovation, every step entrepreneurs take is worth documenting. Qiming Venture Partners will continue to accelerate and empower entrepreneurs, and we invite you to follow along as we spotlight milestone moments for our portfolio companies.
Corporate ESG
Tigermed Receives Top ESG Rating from MSCI
Recently, Qiming Venture Partners portfolio company Tigermed (300347.SZ, 03347.HK) received the highest possible AAA rating in the latest Environmental, Social and Governance (ESG) assessment published by Morgan Stanley Capital International (MSCI). This marks the first time the company has achieved MSCI's top ESG rating, signaling that Tigermed's ESG practices have reached a globally leading level and establishing it as a benchmark enterprise for ESG performance within the industry.
On the environmental front, Tigermed's near-term greenhouse gas reduction targets have been validated by the Science Based Targets initiative (SBTi). The company is actively fulfilling its environmental protection responsibilities through measures including improving its environmental management system, strengthening emissions and resource use management, and promoting digital platforms and green office initiatives. On the social front, Tigermed is advancing digital transformation, actively applying AI technology to optimize clinical trial processes, safeguarding women's employee rights and setting workforce diversity goals, carrying out public welfare projects in medical assistance, education support, and poverty relief through the "Hangzhou Tigermed Public Welfare Foundation," and actively participating in consumption-driven assistance to support rural revitalization. In corporate governance, Tigermed has improved its ESG management and compliance governance systems, with the board providing comprehensive oversight of ESG affairs, the Compliance and ESG Committee directly led by the general manager and managed by the chief compliance officer, 100% coverage of business ethics training, and requirements for new suppliers to sign the "Supplier Code of Conduct" at the admission stage and undergo regular reviews.
Funding News
01/
SANY Hydrogen Raises Hundreds of Millions of Yuan in Series A Round
Led by Qiming Venture Partners
Recently, SANY Hydrogen completed a Series A financing round of several hundred million yuan, led by Qiming Venture Partners. This round fully demonstrates the venture capital community's strong recognition of SANY Hydrogen's core equipment capabilities, leading market position, and broad growth prospects. Building on this momentum, SANY Hydrogen will comprehensively accelerate the innovative R&D and manufacturing upgrade of green hydrogen equipment, resolutely implement its "quality leadership" strategy, and commit to leading the large-scale application of green hydrogen equipment globally.
Founded in August 2022, SANY Hydrogen is the hydrogen energy strategic platform created by global equipment manufacturing leader SANY Heavy Industry to advance China's "dual carbon" goals. Leveraging SANY Heavy Industry's 30-plus years of technical accumulation, supply chain system, and global channels in construction machinery and energy equipment, SANY Hydrogen has introduced "lighthouse factory"-level large-scale manufacturing capabilities, global delivery experience, and lean quality management systems into the water electrolysis hydrogen production field, rapidly breaking through to become a leading green hydrogen equipment enterprise within three years and firmly establishing itself in the industry's top tier.
Chen Nan, Executive Director at Qiming Venture Partners, said: "Green hydrogen is at a critical window transitioning from policy-driven demonstration to market-driven explosion. Enterprises with large-scale, low-cost, and high-reliability delivery capabilities will break through first. Backed by SANY Heavy Industry's 30-plus years of comprehensive advantages in equipment manufacturing, supply chain integration, channel expansion, and global delivery, SANY Hydrogen ranks in the industry's top tier across product definition, process manufacturing, and project delivery. We believe that as the green hydrogen inflection point arrives, SANY Hydrogen will become a core supplier for global green hydrogen infrastructure."
02/
Mech-Mind Robotics Raises Nearly 500 Million Yuan in New Round
Qiming Venture Partners portfolio company Mech-Mind Robotics recently completed a new financing round of nearly 500 million yuan. The funds will be used to accelerate the continuous evolution of Mech-Mind Robotics' embodied intelligence "eyes-brain-hands" full-stack technology, expand its product lines and scenario applications, and further enhance global commercialization and customer service capabilities.
The embodied intelligence "eyes-brain-hands" full-stack technology independently developed by Mech-Mind Robotics can be deeply integrated with robots of various form factors, enabling them with multi-modal perception and autonomous planning capabilities. This allows robots to quickly understand natural language instructions and execute diverse, complex tasks, achieving high generalization across objects, tasks, and environments. This technology system is key to driving robots into thousands of industries, and also foundational to solving the core problem of robots truly "getting work done" — enabling robots to complete tasks stably and efficiently in real production and service environments.
03/
Vivatides Therapeutics Raises Millions of Dollars in Seed Round
Qiming Venture Partners Participates in Investment
Recently, Vivatides Therapeutics (hereinafter referred to as "Vivatides Therapeutics" or "the Company") announced the completion of a multi-million dollar seed financing round, with Qiming Venture Partners participating. The proceeds will be primarily used for preclinical development of the company's extrahepatic-targeted small nucleic acid platform and pipeline.
Founded in 2025, Vivatides Therapeutics' international core team members had years of R&D experience at leading small nucleic acid companies including Arrowhead, Ionis, Alnylam, and Dicerna before founding the company. They led or deeply participated in the development of multiple extrahepatic pipelines, with several projects currently in clinical development, making them one of the few technology-leading teams with hands-on experience in developing both extrahepatic ASO and siRNA pipelines. Founder Dr. Keming Zhou previously led the development of multiple extrahepatic small nucleic acid pipelines and the establishment of related platforms at Arrowhead and Ionis.
Dr. Kan Chen, Partner at Qiming Venture Partners and Co-Head of Healthcare Innovation, said: "We are very pleased to participate in and support Vivatides Therapeutics' seed round. The progress the team has made in extrahepatic-targeted small nucleic acid delivery technology is impressive. This platform technology holds tremendous potential and is expected to unlock entirely new therapeutic opportunities for numerous extrahepatic tissue diseases that currently lack effective treatments. We highly recognize Dr. Keming Zhou and his team's exceptional execution capabilities and continuous innovation, and will fully support Vivatides Therapeutics in accelerating the clinical translation of its innovative therapies, ultimately enabling these breakthroughs to benefit a broader global patient population in urgent need of new treatment options."
Major Partnerships
01/
Hesai Technology Partners with Beonic to Build
Leading Smart Airport Solutions
Beonic, a global leader in AI software development, has unveiled its vision for the smart airport of the future — a data-driven, intelligent decision-making solution designed to reshape airport operational efficiency and the passenger experience. At the core of this solution is Hesai Technology's (NASDAQ:HSAI) compact 3D LiDAR JT series, a Qiming Venture Partners portfolio company. By fusing data from LiDAR, cameras, Wi-Fi, and flight information systems, the system captures a dynamic, full-scene view of airport operations, enabling intelligent decision support for critical functions including queue management, gate scheduling, passenger flow monitoring, and workforce planning.
The JT series is Hesai Technology's newly launched ultra-compact ultra-hemispherical 3D LiDAR for robotics and industrial applications, built on Hesai's fourth-generation proprietary chip architecture. As a platform product, the JT supports multiple configurations — 16-line, 128-line, and 256-line — with ultra-high-definition resolution that easily identifies environmental details and small obstacles. By the end of the second quarter, JT series deliveries had surpassed 100,000 units, achieved in less than five months since launch, quickly gaining traction among global leading customers including Beonic.
02/
Cix Technology Partners with Baidu to Advance
Edge AI Heterogeneous Computing Solutions
Recently, Cix Technology, a Qiming Venture Partners portfolio company, and Baidu jointly released an end-to-end Edge AI solution based on Cix Technology's P1 processor and Baidu's ERNIE 4.5, achieving deep synergy between a domestic high-performance SoC and large language models.
The solution leverages Cix Technology's self-developed P1 processor (6nm process / 12-core Armv9 CPU / 30 TOPS NPU / 45 TOPS total compute) as its heterogeneous computing foundation, deeply integrating with Baidu's ERNIE 4.5 technology ecosystem to build a full-stack closed loop from the chip layer to the model layer to the application layer, setting a new benchmark for edge AI deployment.
03/
Huadong Medicine and DeepWise Establish Deep Collaboration on AI for Science Drug Design Platform Hermite®
Recently, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd. ("Huadong Medicine"), and DeepWise, a Qiming Venture Partners portfolio company, announced a deep collaboration. Huadong Medicine will fully integrate DeepWise's Uni-FEP free energy perturbation calculation tool, marking a solid step forward in the two companies' partnership in drug R&D. This collaboration aims to leverage DeepWise's cutting-edge technology to accelerate Huadong Medicine's drug development process, improve R&D efficiency and quality, and jointly drive the digital and intelligent transformation of pharmaceutical R&D.
Uni-FEP, a core module of DeepWise's Hermite® drug computational design platform, integrates free energy perturbation theory, molecular dynamics, enhanced sampling algorithms, and high-performance computing to efficiently evaluate protein-ligand binding affinity with chemical accuracy. This technological breakthrough addresses the long-standing precision and efficiency challenges in affinity assessment during traditional drug discovery, providing powerful support for lead compound optimization. Beyond evaluating protein-ligand binding free energy, Uni-FEP can be widely applied to ligand selectivity prediction across homologous proteins, protein mutation stability prediction, and improving ADME/T properties, offering a comprehensive solution for drug R&D.
R&D Progress
01/
Abbisko Pharma's Preclinical Study on Pimicotinib for Osteosarcoma Published in Journal of Translational Medicine
Recently, Abbisko Pharma (02256.HK), a Qiming Venture Partners portfolio company, announced that preclinical research on its self-developed CSF-1R inhibitor pimicotinib for osteosarcoma (OS) treatment has been published in Journal of Translational Medicine, an international authoritative translational medicine journal under BioMed Central. The study not only demonstrates pimicotinib's promising potential for expanding into solid tumor indications, but also brings a potential new precision treatment option for osteosarcoma patients.
The Abbisko Pharma research team found that high CSF-1R expression is highly prevalent in osteosarcoma patient samples. The team subsequently evaluated the efficacy of the highly selective CSF-1R inhibitor pimicotinib in cellular and animal models, with results showing effective inhibition of tumor cell proliferation, induction of cell cycle arrest and apoptosis, and significantly enhanced anti-tumor effects when combined with standard chemotherapy. This study is the first to comprehensively and systematically evaluate the pharmacological effects of a CSF-1R small molecule inhibitor in preclinical osteosarcoma models, and the first to reveal the correlation between osteosarcoma CSF-1R expression levels and inhibitor efficacy.
02/
Abbisko Pharma's Clinical Application for ABSK043 Combined with Ali's Glecirasib for Non-Small Cell Lung Cancer Approved in China
Recently, Abbisko Pharma (02256.HK), a Qiming Venture Partners portfolio company, announced that its clinical study application for the combination of its investigational oral small molecule PD-L1 inhibitor ABSK043 with Ali's KRAS G12C inhibitor glecirasib tablets for the treatment of KRAS G12C-mutated non-small cell lung cancer (NSCLC) has been approved by the Center for Drug Evaluation (CDE), National Medical Products Administration. In March of this year, Abbisko Pharma and Ali reached a collaboration agreement for the combination therapy.
Previously, ABSK043 was also combined with Ali's self-developed furmonertinib mesylate tablets for the treatment of advanced non-small cell lung cancer, with the first patient dosed in December 2024.
The latest Phase 1 study results of ABSK043 in patients with advanced solid tumors demonstrated favorable safety and anti-tumor activity, with higher response rates in the PD-L1 high-expression group, EGFR-mutated group, and KRAS-mutated group.
03/
Zai Lab Announces Innovative Medical Device Designation from National Medical Products Administration for Tumor Treating Fields
Recently, Zai Lab (NASDAQ:ZLAB, 09688.HK), a Qiming Venture Partners portfolio company, announced that based on positive results from the Phase 3 PANOVA-3 study, the National Medical Products Administration has granted Innovative Medical Device Designation for Tumor Treating Fields (TTFields) in pancreatic cancer patients. Under this designation, the relevant review will follow the special review procedure for innovative medical devices, with the National Medical Products Administration prioritizing review resource allocation to accelerate the product's registration and market approval process.
The Phase 3 PANOVA-3 study evaluated TTFields combined with gemcitabine and nab-paclitaxel as first-line therapy for unresectable locally advanced pancreatic ductal adenocarcinoma, compared against gemcitabine and nab-paclitaxel alone. The study met its primary endpoint, demonstrating a statistically significant improvement in median overall survival for patients in the TTFields treatment group. Zai Lab participated in this study in Greater China.
04/
LokiBio Holds Phase 2b Lead Site Initiation Meeting for LQ036
LokiBio, a Qiming Venture Partners portfolio company, recently announced the successful lead site initiation meeting for its core inhaled product LQ036 (an IL-4Rα-targeting single-domain antibody) at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. This marks the formal launch of LQ036 — the world's first inhaled single-domain antibody — into its Phase 2b randomized, double-blind, placebo-controlled, multicenter clinical study to evaluate efficacy and safety in patients with poorly controlled asthma.
Dr. Yakun Wan, founder, Chairman, and CEO of LokiBio, stated: "LQ036 is the first clinical-stage candidate from LokiBio's proprietary inhaled single-domain antibody platform, Aerobody®. Previous study data have shown encouraging efficacy and safety profiles. This Phase 2b study builds on that foundation and carries significant importance."
05/
Antengene's CLDN18.2 ADC ATG-022 Granted Breakthrough Therapy Designation
Antengene (06996.HK), a Qiming Venture Partners portfolio company, recently announced that its self-developed CLDN18.2 antibody-drug conjugate (ADC) ATG-022 has been included in the National Medical Products Administration's (NMPA) Center for Drug Evaluation (CDE) breakthrough therapy designation program. The indication is for the treatment of CLDN18.2-positive, HER2-negative unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJ) in patients who have received two or more prior lines of therapy.
The breakthrough therapy designation is a key initiative by the NMPA to accelerate the development and approval of new drugs with significant clinical advantages. Following inclusion in the program, ATG-022 will receive prioritized review resources, shortening its overall development timeline and bringing benefits to Chinese patients sooner. Previously, ATG-022 also received Orphan Drug Designation (ODD) from the FDA for the treatment of gastric and pancreatic cancers, fully demonstrating its clinical potential across multiple tumor types.
06/
Thorough Future Contributes to Beijing Chest Hospital Research Published in International Journal
A study conducted by Beijing Chest Hospital in collaboration with Thorough Future, a Qiming Venture Partners portfolio company, has been published in the Journal of Translational Medicine. The research focuses on personalized pre-treatment assessment for first-line EGFR-TKI therapy in advanced EGFR-mutant non-small cell lung cancer (NSCLC) using multimodal weakly supervised learning technology.
This study marks the first integration of pre-treatment H&E whole-slide imaging (WSI) with multidimensional clinical variables to construct a multimodal weakly supervised AI system. The system can simultaneously determine patient response status and quantitatively output progression-free survival (PFS, precise to the month) before first-line EGFR-TKI therapy, establishing a new evidence-based foundation and technical paradigm for precision decision-making in advanced EGFR-mutant NSCLC.
Corporate Development
01/
SinoUnited Health Launches Longevity Clinic with Official Mayo Clinic Guidance
Under the official guidance of Mayo Clinic, a globally renowned high-quality medical institution, SinoUnited Health — a Qiming Venture Partners portfolio company — has officially launched its Longevity Clinic in Shanghai.
Dr. Haoying Shi, founder and CEO of SinoUnited Health, President of Shanghai SinoUnited Hospital, and Director of Cardiovascular Medicine, revealed that the clinic is rooted in nearly a decade of SinoUnited Health's health management practice: serving tens of thousands of families through continuous physical examinations and interventions, standardized processes and evidence-based data systems, and collaborative experience from its "general practice + specialty" multidisciplinary center.
The Longevity Clinic took over a year to prepare. SinoUnited Health assembled a multidisciplinary team spanning cardiovascular medicine, endocrinology, neurology, sports medicine, nutrition, sleep medicine, psychology, general practice, and traditional Chinese medicine. Combining molecular and proteomics, biomarkers, advanced imaging, and digital platforms with the latest global lifestyle medicine evidence, the clinic fully introduces Mayo Clinic's longevity medicine philosophy — built on deep evidence-based medical foundations — and its advanced chronic disease and anti-aging management models to China.
02/
Pulnovo Medical Appoints Dr. Francis Duhay as Global Chief Medical Officer
Pulnovo Medical, a Qiming Venture Partners portfolio company, recently announced that Dr. Francis Duhay has officially joined the company as Global Chief Medical Officer. A veteran cardiothoracic surgeon with extensive experience in innovative device clinical development and commercialization, Dr. Duhay will lead and oversee Pulnovo Medical's global medical affairs, clinical, and regulatory strategy, accelerating the company's globalization efforts.
Dr. Francis Duhay is a seasoned medical expert with over 25 years of experience in clinical practice, device R&D, and global executive leadership. Throughout his career, he led and advanced breakthrough technologies including transcatheter aortic valve replacement (TAVR), now regarded as one of the most successful cardiovascular procedures in medical device history and widely adopted in over 80 countries and regions. Prior to joining Pulnovo Medical, Dr. Duhay successfully supported 88 clinical studies covering structural heart disease, gastroenterology, urology, respiratory, ENT, gynecology, general surgery, and neurovascular specialties. He possesses systematic expertise in global registration, regulatory compliance, and clinical management strategy, and has maintained close collaboration with global regulatory and payer bodies including the FDA and the Centers for Medicare & Medicaid Services (CMS).
Product Launches
01/
Roborock Releases H50 Cordless Stick Vacuum and H50 Pro Smart Self-Emptying Vacuum
Roborock (688169.SH), a Qiming Venture Partners portfolio company, recently released the H50 cordless stick vacuum and the H50 Pro smart self-emptying vacuum.
The H50 cordless stick vacuum features an innovative "flexible bend" design enabling 180° folding. Its brush head supports multi-angle flexible adjustment, easily reaching dead spots under sofas and beds. The vacuum also incorporates 140° wide-angle green light dust detection technology, making dust mites, dander, and other allergens visible. Core power comes from 260AW strong suction, penetrating deep into floor gaps and carpet fibers to lift stubborn dust and allergens. Notably, the H50 is optimized for sensitive individuals with an "allergen-grade" filtration system. The entire machine features a 5-stage ultra-fine filtration network with a 99.99% mite removal rate.
The H50 Pro smart self-emptying vacuum supports 90 days of hands-free dust disposal, using a 2.5L silver-ion antibacterial dust bag with intelligent compression storage technology. The entire machine features 8-stage filtration that traps allergens as small as 0.1 microns, earning international authoritative certification for allergy care. Additionally, the H50 Pro incorporates a full-chain zero-tangle design with triple anti-tangle protection across the floor brush, mite removal brush, and dust cup. The product features an ergonomically designed storage height, enables edge-to-edge cleaning on both sides, and delivers 80 minutes of extended runtime with all-day automatic charging.
02/
Insta360 Launches 4K Flagship Pocket Camera GO Ultra
Recently, Qiming Venture Partners portfolio company Insta360 (688775.SH) released the GO Ultra, its first flagship-quality pocket camera and a new premium sub-line in the GO series. The device features a distinctive "tiny cube" design that combines lightweight construction with professional performance — the main unit weighs just 53g, while total runtime exceeds 200 minutes. It enables hands-free, first-person perspective shooting for imperceptible recording, serving both everyday documentation and sports scenarios.
It packs a 1/1.28-inch large sensor and a 5nm AI chip, supporting 4K 60fps high-definition video capture. An upgraded "Night Mode" enhances performance in low-light conditions. The minimalist body comes in black and white colorways, doubling as a fashion accessory. Through its compact form factor and powerful internals, the GO Ultra aims to become the shooting companion of choice for sports imaging enthusiasts, vlog creators, and families.
03/
Zhipu AI Releases AutoGLM 2.0
Recently, Qiming Venture Partners portfolio company Zhipu AI launched AutoGLM 2.0, elevating Agent applications to new heights.
AutoGLM 2.0 is the world's first smartphone Agent available to everyone. It also pioneers a new technical paradigm combining Agents with cloud phones and cloud computers — without occupying users' physical devices. Breaking through hardware limitations, it operates on any device in any scenario, acting on users' behalf. AutoGLM 2.0 is powered by domestic models (GLM-4.5, GLM-4.5V) and possesses comprehensive capabilities in reasoning, coding, and multimodal understanding.
AutoGLM is driven by Zhipu AI's latest open-source SOTA language model GLM-4.5 and visual reasoning model GLM-4.5V. It maximizes the native capabilities of foundation models and incorporates multiple breakthroughs in "end-to-end asynchronous reinforcement learning," enabling it to complete diverse tasks including reasoning, coding, research, Agentic operations, and GUI manipulation — flexibly calling upon the most suitable "brain" for each execution as needed.
04/
PETKIT Hosts 2025 Global Autumn Product Launch
Recently, Qiming Venture Partners portfolio company PETKIT held its 2025 Global Autumn Product Launch in Wuxi, Jiangsu Province, unveiling an open-design AI fully automatic cat litter box, a fully automatic wet food feeder, a second-generation smart visual feeder, and the PETKIT Smart Water Fountain MAX 2.
The open-design AI fully automatic cat litter box features crystal cat litter with a unique porous adsorption molecular structure that rapidly absorbs moisture and odors, plus an active deodorization system powered by the Odor Elimination Cube N60 for proactive smell control. The fully automatic wet food feeder supports fully customizable feeding schedules, delivering fresh wet food around the clock with the same smart convenience as dry food dispensers. In the second-generation smart visual feeder, a completely upgraded chip delivers 2.4x computing power and 7x faster single-frame image processing, enabling AI cat face recognition and feeding record generation. The PETKIT Smart Water Fountain MAX 2 revolutionizes traditional cleaning methods with heat-resistant materials throughout the water pathway — simply pour in 100°C boiling water and activate one-touch mode for circulating sterilization from inlet to outlet, effectively reducing 99.9% of bacteria.
05/
Berry Genomics Announces Official Launch of HiFi Long-Read Whole Genome Testing Product
Recently, Qiming Venture Partners portfolio company Berry Genomics (000710.SZ) announced the official launch of its HiFi long-read whole genome testing (HiFi LR-WGS) product.
Compared to multi-technology approaches, HiFi LR-WGS demonstrates the ability to accurately detect all types of clinically relevant variants through a single method, providing a more comprehensive solution for rare disease diagnosis.
The product is suitable for complex genetic disease detection, avoiding missed and false detections of traditional methods while improving diagnostic yield. Without PCR amplification, it can sequence each individual DNA molecule, featuring long reads, high accuracy, no GC bias, and single-molecule resolution — with self-correction achieved through rolling-circle sequencing of individual DNA molecules. The product effectively reduces diagnosis time and medical costs for patients with genetic diseases, does not rely on family or proband analysis, directly distinguishes cis/trans configurations, and supports early clinical diagnosis and treatment.
Technological Strength
01/
WeRide Robotaxi Enters Operation in Switzerland, Transforming Local Mobility
As part of the iamo (Intelligent Automated Mobility) pilot project, Qiming Venture Partners portfolio company WeRide (NASDAQ:WRD) has put its Robotaxi into operation in Switzerland, conducting mapping work on public roads in the Fürttal region of Zurich Canton, the Villmergen region of Aargau Canton, and the Killwangen region. The mapping captures high-definition digital maps containing critical information such as lane markings, lane widths, traffic signals, and curb heights.
Initiated by Swiss Transit Lab (STL) and Swiss Federal Railways (SBB CFF FFS), with WeRide providing autonomous driving technology, the project is transforming mobility in Switzerland.
02/
DeepWay Completes First Batch of New Energy Heavy Truck Xingtu Deliveries and Signs 500-Unit Follow-On Order
Recently, Qiming Venture Partners portfolio company DeepWay completed the first 100-unit delivery of its Xingtu short-wheelbase model together with Yongfeng Lingang, Gangtou Special Steel, Jiaoyun Group, Rokin, and other major logistics enterprises, signing an additional 500-unit order on-site. This marks another milestone in DeepWay's scaled application of new energy heavy trucks.
Shangshang Xu, DeepWay co-founder and CMO, stated: "This 100-unit delivery and 500-unit signing for Xingtu marks a further step in the scaled application of DeepWay's new energy heavy trucks. Taking this delivery and signing as our starting point, we will leverage Linyi's powerful logistics industry foundation to ensure efficient vehicle operations, working hand-in-hand with all our partners to write a new chapter in Linyi's green logistics."
03/
DeepWay Hosts First Test Drive Event in New Zealand
Recently, Qiming Venture Partners portfolio company DeepWay held its first test drive event in New Zealand, attracting over 30 customers including New Zealand's largest dairy trading enterprise, globally renowned logistics companies, and core local freight operators for test drives and rides.
The vehicle showcased this time is a right-hand-drive version tailor-made for the New Zealand market, equipped with a 600kWh high-capacity battery that delivers over 440 kilometers of range under full-load conditions. The model has been certified by New Zealand's NZTA (New Zealand Transport Agency) and features the "Tianji · Suixing" combined driver-assistance system, offering adaptive cruise control, lane keeping, emergency braking assist, and other advanced driving assistance functions. Additionally, the vehicle can be fitted with the "Tianji · Yanxing" platooning system, which enables a single driver to simultaneously control four vehicles in coordinated convoy driving, effectively improving long-haul transport efficiency and road safety.
04/
Pulnovo Medical to Appear at European Society of Cardiology Congress
Qiming Venture Partners portfolio company Pulnovo Medical will appear at the ESC Congress 2025, held in Madrid, Spain. At that time, Pulnovo Medical will hold a grand launch ceremony for the European market debut of its PADN product series, officially opening a new chapter in the European market.
During the congress, Pulnovo Medical will present a multi-dimensional immersive experience, fully demonstrating the positive changes that PADN technology brings to patients' lives. The exhibition area will feature a dedicated interactive experience zone, integrating a professional knowledge exhibition area with hands-on surgical model demonstrations, helping attendees intuitively perceive the clinical advantages and therapeutic value of PADN technology. Leading experts from Italy, Georgia, Portugal, the United States, and China will be present on-site to share academic insights and clinical practices based on real-world cases. The recovery journeys of overseas patients will also be vividly presented through video, further highlighting the actual efficacy and application prospects of this technology.
Corporate Honors
SPEEDIANCE Speediance Wins
2025 Global Tech Awards
Recently, the Global Tech Awards were announced. Qiming Venture Partners portfolio company SPEEDIANCE Speediance was selected for the Global Tech Awards - Fitness Technology (FitTech) list with its Gym Monster 2.
This award is one of the world's most influential technology honors, recognizing technology solution providers and service providers with outstanding performance in technological innovation, creative breakthroughs, and execution. Past winners include top global hardware manufacturers, artificial intelligence platforms, and health technology brands. The winning products represent not only industry-leading technology but also global benchmarks and innovative paradigms in their respective fields.
Past Issues
Qiming Weekly | Qiming Venture Partners Portfolio Company Financing and Updates Vol. 30, 2025
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through mergers and acquisitions. More than 80 companies have become recognized unicorns or super-unicorns.
Many of Qiming Venture Partners' portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Insta360 (688775.SH), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), Sinocelltech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.